Table 2.
Comparison of clinicopathological characteristics between right-sided and left-sided in stage I, II and III colon cancer.
| Characteristic | Stage I | Stage II | Stage III | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Right-sided cancer (N = 66) |
Left-sided cancer (N = 122) |
P value | Right-sided cancer (N = 151) |
Left-sided cancer (N = 171) |
P value | Right-sided cancer (N = 168) |
Left-sided cancer (N = 339) |
P value | |
| Age (years) | 64.5 (57–74) | 62 (55.8–67.3) | 0.16 | 70 (59–79) | 66 (58–77) | 0.12 | 68 (60–77.75) | 65 (57–76) | 0.11 |
| Sex, Male, N (%) | 28 (42.4%) | 71 (58.2%) | 0.04 | 68 (45%) | 96 (56%) | 0.047 | 86 (51.1%) | 190 (56.0%) | 0.30 |
| Body mass index | 24.9 ± 3.7 | 25.9 ± 4.4 | 0.44 | 23.6 ± 4.3 | 24.2 ± 4.3 | 0.25 | 23.4 ± 4.6 | 24.2 ± 3.8 | 0.04 |
| Patient origin, N (%) | 0.74 | 0.13 | 0.65 | ||||||
| Elective operation | 62 (93.9%) | 116 (95.1%) | 111 (73.5%) | 138 (80.7%) | 128(76.1%) | 265(78.2%) | |||
| Emergency operation | 4 (6.1%) | 6 (4.9%) | 40 (26.5%) | 33 (19.3%) | 40(23.9%) | 74(21.8%) | |||
| Operation method, N (%) | 0.35 | 0.02 | < 0.01 | ||||||
| Open surgery | 21 (31.8%) | 31 (25.4%) | 86 (57.0%) | 75 (43.9%) | 95 (56.5)% | 132 (38.9%) | |||
| Minimal invasive surgery | 45 (68.2%) | 91 (74.6%) | 65 (43.0%) | 96 (56.1%) | 73 (43.5%) | 207 (61.1%) | |||
| CEA | 2.1 (1.4–3.3) | 2.0 (1.4–3.0) | 0.80 | 3.8 (1.9–10.1) | 4.4 (2.1–10.2) | 0.54 | 4.28 (2.0–13.4) | 4.3 (2.2–11.3) | 0.54 |
| Tumor size (cm) | 2.3 (1.5–3.7) | 2.4 (1.5–3.5) | 0.97 | 5.0 (3.5–7.0) | 4.5 (3.5–6.0) | 0.19 | 5.0 (4.0–6.5) | 4.2 (3.2–5.5) | < 0.01 |
| Lymphovascular invasion, N (%) | 8 (12.1%) | 23 (18.9%) | 0.24 | 61 (40.4%) | 49 (28.7%) | 0.03 | 116 (69.0%) | 232 (68.4) | 0.89 |
| Perineural invasion, N (%) | 8 (12.1%) | 6 (4.9%) | 0.07 | 48 (31.8%) | 50 (29.2%) | 0.62 | 92 (54.8%) | 174 (51.3%) | 0.47 |
| Tumor grade, N (%) | 0.03 | 0.01 | 0.48 | ||||||
| Grade 1–2 | 62 (93.9%) | 121 (99.2%) | 133 (88.1%) | 164 (95.9%) | 157 (93.5%) | 322 (95.0%) | |||
| Grade 3–4 | 4 (6.1%) | 1 (0.8%) | 18 (11.9%) | 7 (4.1%) | 11 (6.5%) | 17 (5.0%) | |||
| T stage, N (%) | 0.57 | 0.13 | 0.02 | ||||||
| T1 | 35 (53.0%) | 70 (57.3%) | 6 (3.6%) | 16 (4.7%) | |||||
| T2 | 31 (47.0%) | 52 (42.7%) | 8 (4.8%) | 31 (9.1%) | |||||
| T3 | 118 (78.1%) | 145 (84.8%) | 96 (57.1%) | 206 (60.8%) | |||||
| T4 | 33 (21.9%) | 26 (15.2%) | 58 (34.5%) | 86 (25.4%) | |||||
| N stage, N (%) | 0.64 | ||||||||
| N0 | 66 | 122 | 151 | 171 | |||||
| N1 | 106 (63.1%) | 221 (65.2%) | |||||||
| N2 | 62 (36.9%) | 118 (34.8%) | |||||||
| No. of lymph node harvested | 22 (18.8–31) | 17 (14–24) | < 0.01 | 24 (18–35) | 22 (17–29) | 0.02 | 29 (21–38.8) | 22 (17–30) | < 0.01 |
| Adjuvant chemotherapy, N (%) | 1 (1.5%) | 0 (0%) | 0.18 | 72 (47.7%) | 75 (43.9%) | 0.49 | 124 (73.8%) | 248 (73.2%) | 0.88 |
| K-ras mutation, no. of positive/No. of test (%) | 10/23 (43.5%) | 13/32 (40.6) | 0.84 | 34/77 (44.2%) | 22/76 (28.9%) | 0.04 | 50/94 (53.2%) | 58/186 (31.2%) | < 0.01 |
| dMMR, no. of positive/no. of test (%) | 3/8 (37.5%) | 4/7 (57.1%) | 0.45 | 12/26 (46.2%) | 3/20 (15%) | 0.03 | 10/21 (47.6%) | 3/28 (10.7%) | < 0.01 |
| MSI-H, no. of positive/no. of test (%) | 0/1 | 0/3 | 4/10 (40%) | 1/7 (14.3) | 0.25 | 1/9 (11.1) | 0/3 | 0.55 | |
| R1 resection, N (%) | 0 | 1 (0.8%) | 0.46 | 4 (2.6%) | 6 (3.5%) | 0.66 | 13 (7.7%) | 12 (3.5%) | 0.04 |
| Follow time (month) | 43.3 (29.5–67.4) | 51.8 (30.1–78.1) | 0.34 | 42.6 (15.6–66.0) | 45.6 (28.5–73.3) | 0.43 | 35.3 (19.5–58.5) | 38.6 (22.0–61.1) | 0.12 |
Significant values are in bold.
CEA carcinoembryonic antigen, dMMR Deficient mismatch repair, MSI-H microsatellite instability-high.